Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rollover study of capmatinib after prior Novartis trials
2016-005144-42Phase 2Active
- Sponsor
- Novartis
- Start
- Mar 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capmatinib in cancer, sponsored by Novartis. Primary endpoint: Frequency and severity of AEs/SAEs. Started Mar 2017; status: active.
02
Drugs
capmatinib
03
Conditions
cancer
Beyond the preview
Go deeper on 2016-005144-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-005144-42.